The antiangiogenic agent linomide inhibits tumor necrosis factor-α secretion via inhibition of its synthesis
- 1 September 1996
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 29 (3), 183-190
- https://doi.org/10.1002/(sici)1097-0045(199609)29:3<183::aid-pros4>3.0.co;2-f
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The implications of angiogenesis for the biology and therapy of cancer metastasisCell, 1994
- Tumor Necrosis Factor, Other Cytokines and DiseaseAnnual Review of Cell Biology, 1993
- Linomide, a novel immunomodulator that prevents death in four models of septic shockEuropean Journal of Immunology, 1993
- The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cellsInternational Journal of Immunopharmacology, 1993
- Treatment of Minimal Residual Diseasein Myeloid Leukemia—The Immunotherapeutic Options with Emphasis on LinomideLeukemia & Lymphoma, 1993
- Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophagesBiochemistry, 1990
- Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.The Journal of Experimental Medicine, 1990
- Cyclosporin a modulation of tumor necrosis factor gene expression and effects in vitro and in vivo.The Journal of Immunology, 1990
- Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level.The Journal of Experimental Medicine, 1990
- Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators.Proceedings of the National Academy of Sciences, 1986